Transactions

Our broad-based transaction experience extends across a range of situations, industries and enterprise values

Type

Industry

Republic of Ecuador

Announced: January 27, 2026
Value: $4.0 billion
Status: Closed

Exclusive financial advisor to the Republic of Ecuador on its Eurobond issuance

SEEQC, Inc.

Announced: January 16, 2026
Value: $1 billion
Status: Pending

Financial advisor to SEEQC on its agreement to combine with Allegro Merger Corp, supported by a $65 million PIPE financing

Forbright, Inc.

Announced: June 11, 2026
Value: $142 million
Status: Closed

Passive co-manager on Forbright's IPO pricing

Bayer AG

Announced: September 16, 2026
Value: €3bn
Status: Closed

Centerview as financial advisor to the Apollo Funds on its capital solution transaction for Bayer AG

Clinical ink

Status: Pending

Centerview as exclusive financial advisor to Clinical ink and GI Partners on the sale of a 50% equity interest in Clinical ink to Ardan Equity

Sauer Brands

Announced: September 4, 2026
Status: Pending

Centerview as financial advisor to Sauer Brands on their sale to Watkins

GOODLES

Announced: September 2, 2026
Status: Pending

Centerview as exclusive financial advisor to GOODLES on their sale to Barilla

Fullscript

Announced: August 31, 2026
Status: Pending

Centerview as exclusive financial advisor to Fullscript on their sale to L Catterton and Atlas Partners

Merida

Announced: August 31, 2026
Value: Up to $2.875bn
Status: Pending

Exclusive financial advisor to Merida on its sale to Eli Lilly

Algonquin Power & Utilities Corp.

Announced: August 28, 2026
Value: $127mm
Status: Pending

Centerview as exclusive financial advisor to Algonquin on its sale of its 64% stake in Suralis S.A. to a fund managed by Toesca S.A. Administradora General de Fondos

Precision Medicine Group

Announced: August 25, 2026
Value: $2.25bn
Status: Pending

Centerview as co-lead financial advisor to Precision and Blackstone on its sale to McKesson

Merieux NutriSciences

Status: Pending

Centerview as Exclusive financial advisor to Merieux NutriSciences on its acquisition of Certified Group

Bentley Systems

Announced: August 12, 2026
Status: Pending

Centerview as exclusive financial advisor to Bentley Systems on their divestiture of its IBM Maximo consulting, implementation and hosting business, Cohesive Solutions to Naviam

Xylem

Announced: August 11, 2026
Value: $1.46bn
Status: Pending

Centerview as exclusive financial advisor to Xylem on their acquisition of Cornell and Roper Pump Businesses

Eurazeo SE

Status: Pending

Centerview as exclusive financial advisor to Eurazeo on their investment in Aroma-Zone

Apollo Global Management

Announced: August 5, 2026
Value: $1bn
Status: Pending

Centerview as exclusive financial advisor to Apollo on their investment in JV with Starwood REIT

KKR

Announced: August 3, 2026
Value: $5.7bn
Status: Pending

Centerview as financial advisor to KKR on their acquisition of Integer.

Santander

Announced: July 31, 2026
Value: $2.2bn
Status: Pending

Centerview as financial advisor to Santander on their exchange offer to acquire the outstanding shares of Santander Brazil

MiMedx

Announced: July 29, 2026
Value: $350mm
Status: Pending

Centerview as exclusive financial advisor to MiMedx on their acquisition of Sanara Medtech.

Kuwait Petroleum Corporation

Announced: July 27, 2026
Value: $16bn
Status: Pending

Centerview as financial advisor to KPC on their lease-and-leaseback partnership involving its crude oil export pipeline network with Blackstone, Brookfield and KKR consortium.

BioLife Solutions

Announced: July 22, 2026
Value: $1.5bn
Status: Pending

Centerview as exclusive financial advisor to BioLife Solutions on their sale to Repligen

Personalis

Announced: July 20, 2026
Value: $1.9bn
Status: Pending

Centerview as lead advisor to Personalis on their sale to Tempus AI

Batibig

Status: Pending

Centerview Partners as exclusive financial advisor to Batibig's co-founders, management and shareholders on their exclusive negotiations with Charterhouse Capital Partners.

Thomson Reuters

Announced: July 14, 2026
Value: $500mm
Status: Pending

Centerview as Exclusive Financial Advisor to Thomson Reuters on its sale of a 51% equity stake in its Global Prints business to KKR.

Memo Therapeutics

Announced: July 1, 2026
Value: $800mm
Status: Pending

Centerview as exclusive financial advisor to Memo Therepeutics on their sale to Ipsen

Schneider Electric

Announced: June 30, 2026
Value: $3.1bn
Status: Pending

Centerview as exclusive financial advisor to Schneider Electric on their acquisition of Cognite

Nuvalent

Announced: June 9, 2026
Value: $10.6bn
Status: Pending

Centerview partners as exclusive financial advisor to Nuvalent

Wiley

Announced: June 2, 2026
Value: £337mm
Status: Pending

Centerview as exclusive financial advisor to Wiley on their acquisition of Emerald from Cambridge Information Group

Tractor Supply Company

Announced: May 28, 2026
Status: Closed

Exclusive Financial Advisor to Tractor Supply Company on their acquisition of VIP Petcare

Curevo Vaccine

Announced: May 26, 2026
Value: Up to $1.5bn
Status: Pending

Financial advisor to Curevo on its sale to Eli Lilly

Equity Residential

Announced: May 21, 2026
Value: $69bn
Status: Pending

Centerview served as lead financial advisor to Equity Residential in their merger with AvalonBay Communities

Emalex Biosciences

Announced: April 29, 2026
Value: Up to $900mm
Status: Pending

Financial Advisor on its sale to Teva

KalVista Pharmaceuticals Inc.

Announced: April 29, 2026
Value: $1.9bn
Status: Pending

Financial Advisor to KalVista on its sale to Chiesi

Neurona

Announced: April 17, 2026
Value: Up to $1.15bn
Status: Pending

Centerview as exclusive financial advisor to Neurona on its sale to UCB

Gilead

Announced: April 7, 2026
Value: Up to $5.0bn
Status: Pending

Financial advisor to Gilead on its acquisition of Tubulis

Soleno

Announced: April 6, 2026
Value: $2.9bn
Status: Pending

Lead financial advisor to Soleno on its sale to Neurocrine

TMRW Life Sciences

Announced: April 2, 2026
Status: Pending

Centerview as sole financial advisor to TMRW on their merger and Series E

Versigent

Announced: April 1, 2026
Status: Pending

Centerview as financial advisor to Aptiv in its separation of Versigent

Showing 1 to 38 of 38
Centerview Partners takes a “One Firm” approach to deliver unmatched intellectual capital and integrity to all of our clients. We have industry-leading expertise in:

At Centerview Partners, our success depends on our people, and we are always looking for talented individuals. Please let us know if you would like to learn more about a career at Centerview.
Our Partners have worked on many of the largest and most complex transactions and corporate situations around the globe over the course of their careers. Learn more about who we are.
New York

Centerview Partners LLC


31 West 52nd Street

22nd Floor

New York, New York 10019

(212) 380-2650 | Tel
(212) 380-2651 | Fax
London

Centerview Partners UK LLP


1 Sherwood Street

6th Floor

London W1F 7BL

02074099700 | Tel
02074099704 | Fax
Paris

Centerview Partners France SCS


51 Avenue Hoche


Paris 75008

0180200620 | Tel
0180200621 | Fax
Menlo Park

Centerview Partners LLC


1302 El Camino Real

Suite 350

Menlo Park, California 94025

(650) 822-5800 | Tel
(650) 822-5801 | Fax
San Francisco

Centerview Partners LLC


555 California Street

Suite 4300

San Francisco, California 94104

(415) 400-0900 | Tel
(415) 400-0901 | Fax





Copyright © 2008 - 2026 Centerview Partners Holdings LP. All Rights Reserved. | Privacy and Other Notices

Centerview Partners LLC, member SIPC